Expertise in
7
conditions

Yuichi Yamasaki

Kagoshima, JP 
Expertise in
7
conditions
Kagoshima, JP 

Overview

Yuichi Yamasaki practices practicing medicine in Kagoshima, Japan.

Yamasaki is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Blau Syndrome, Juvenile Idiopathic Arthritis (JIA), Muckle-Wells Syndrome, and Neonatal Onset Multisystem Inflammatory Disease.

They are actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Locations

Kagoshima, Japan
Other Locations
Ube, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Combination product
Study Drug: Belimumab
Study Phase: Phase 2
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

23 Total Publications

Novel susceptible human leukocyte antigens allele in juvenile dermatomyositis: A study in Japanese patients.
Novel susceptible human leukocyte antigens allele in juvenile dermatomyositis: A study in Japanese patients.
Journal: Pediatrics and neonatology
Published: December 17, 2025

Frequently Asked Questions about Yuichi Yamasaki

Is Yuichi Yamasaki a top-rated expert for Blau Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Yuichi Yamasaki is classified as an Distinguished expert for Blau Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yuichi Yamasaki participate in research or clinical trials?

Yes. Yuichi Yamasaki has published 23 articles and abstracts on conditions like Blau Syndrome. You can view a list of Yuichi Yamasaki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yamasaki's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile